Study of linperlisib for people with lymphoma
Treatments studied
Part of Cancer clinical trials.
This real-world study looks at how linperlisib works for treating lymphoma in everyday clinical care. It may help doctors understand whether this medicine is safe and useful for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have a doctor-confirmed diagnosis of lymphoma
- Agree to join the study and sign informed consent
- Be willing and able to cooperate with study check-ins and data collection
- Your care team decides linperlisib could be used for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial tests a combination of two drugs, linperlisib (a PI3K inhibitor) and rituximab, for people whose indolent (slow-growing) non-Hodgkin lymphoma has come back or stopped responding to treatment. It aims to see if adding linperlisib to rituximab can help shrink tumors.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
Hear when a new Focus on the Lymphoma Including B/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.